LeukoDx Announces Appointment Of Dr. Ephraim Carlebach As Senior Vice President R&D

TOWSON, MD and JERUSALEM, ISRAEL--(Marketwired - September 30, 2014) -

LeukoDx Inc., the creator of the Accellix automated flow cytometry platform, today announced the appointment of Ephraim Carlebach, PhD, as Senior Vice President R&D.

Dr. Carlebach has over 30 years of experience in the design and management of complex R&D projects, specializing in medical devices and real-time systems. He has a proven and solid track record in efficiently managing R&D budgets and multidisciplinary design teams delivering state-of-the-art, high quality products. Prior to joining LeukoDx, Dr. Carlebach held senior positions at Arad Technologies, Orsense, Applisonix, Oridion Medical and Scitex.

“Dr. Carlebach is a strong and collaborative leader with wide-ranging technological competence and broad experience in all facets of medical device development up to the release of a commercial product and its support in the field,” said Julien Meissonnier, President & CEO, LeukoDx.

Dr. Carlebach added: “I am honored to have the opportunity to lead this talented R&D team to fulfill our mission and find new ways to discover, develop and deliver innovative diagnostic applications.”

About LeukoDx Inc.

LeukoDx’s mission is to deliver cost-effective, highly sensitive and actionable diagnostic information at the point of care via a novel automated IVD flow cytometry platform. Founded in 2009, LeukoDx’s technology is based on technology initially developed for NASA at CalTech. To date, the Company has developed a compact reader for single use test-specific cartridges, and an application for the rapid identification of sepsis, a condition associated with high morbidity and mortality with no existing rapid diagnostic test.